Author: Steve Kopczak

LitAlert ~~ GeneLit.com

    • Genetic variants in African-American and Hispanic patients with breast cancer.
    • Dutta P, Keung MY, Wu Y, Vadgama JV.
    • Oncol Lett. 2022 Dec 16 [eCollection 2023 Feb];25(2):51. doi: 10.3892/ol.2022.13637.

    • Long-term risk of cancer among the first-degree relatives of epithelial ovarian cancer patients: A cohort study with 48 years of follow up.
    • Kotaniemi-Talonen L, Pukkala E, Aittomäki K, Auranen A.
    • Acta Obstet Gynecol Scand. 2023 Jan 16. doi: 10.1111/aogs.14504. Epub ahead of print.

    • Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.
    • Nukaya T, Sumitomo M, Sugihara E, Takeda M, Nohara S, Tanishima S, Takenaka M, Zennami K, Takahara K, Shiroki R, Saya H.
    • Cancer Med. 2023 Jan 16. doi: 10.1002/cam4.5617. Epub ahead of print.

    • Factors that influence the management recommendations breast surgeons provide to women with pathogenic variants in moderate penetrance breast cancer susceptibility genes.
    • Vanderwal A, Lewis J, Basil J, Atzinger C, Widmeyer K.
    • J Genet Couns. 2023 Jan 15. doi: 10.1002/jgc4.1674. Epub ahead of print.

    • A case report of biallelic CHEK2 heterozygous variant presenting with breast cancer.
    • Soleimani T, Bourdon C, Davis J, Fortes T.
    • Clin Case Rep. 2023 Jan 11 [eCollection 2023 Jan];11(1):e6820. doi: 10.1002/ccr3.6820.

    • First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer.
    • Roy S, Ghosh J, Ganguly S, Biswas B, Bhaumik J.
    • Cureus. 2022 Dec 13;14(12):e32493. doi: 10.7759/cureus.32493.

    • A Glance at Molecular Advances in Cancer Genetics: A Baffling Puzzle Still to Be Solved.
    • Ghiorzo P, Bruno W.
    • Int J Mol Sci. 2023 Jan 11;24(2):1394. doi: 10.3390/ijms24021394.

    • Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review.
    • Miglietta F, Fabi A, Generali D, Dieci MV, Arpino G, Bianchini G, Cinieri S, Conte PF, Curigliano G, De Laurentis M, Del Mastro L, De Placido S, Gennari A, Puglisi F, Zambelli A, Perrone F, Guarneri V.
    • Cancer Treat Rev. 2023 Jan 6;114:102511. doi: 10.1016/j.ctrv.2023.102511. Epub ahead of print.

    • Development and Clinical Applications of an Enclosed Automated Targeted NGS Library Preparation System.
    • Shi C, Feng Y, Sun R, Chen J, Zhao Y, Wang Z, Xie S, Zhou J, Yang L, Cao X, Feng J, Zhang C, Wei B, Wang X, Chang Y, Zhao J, Wang Z, Zheng J, Liu J, Chantratita W, Xiong L, Zhang D, Chen C, Ma J.
    • Clin Chim Acta. 2023 Jan 7:117224. doi: 10.1016/j.cca.2023.117224. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
    • Bellier C, Gladieff L, Le Du F, Berton D, Bonnard C, Suau D, Richard AC, Brenner O, Lahouegue A, Freyer G, Floquet A, Frank S, Kfoury M.
    • Drugs Real World Outcomes. 2023 Jan 11. doi: 10.1007/s40801-022-00349-9. Epub ahead of print.

    • A Glance at Molecular Advances in Cancer Genetics: A Baffling Puzzle Still to Be Solved.
    • Ghiorzo P, Bruno W.
    • Int J Mol Sci. 2023 Jan 11;24(2):1394. doi: 10.3390/ijms24021394.

    • Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom [Clinically relevant molecular pathological diagnostics in breast cancer].
    • Rodepeter FR, Teply-Szymanski J, Romey M, Grass A, Erber R, Lebeau A, Mack EKM, Tarawneh TS, Gremke N, Boekhoff J, Wündisch T, Wagner U, Jank P, Denkert C.
    • Pathologie (Heidelb). 2023 Jan 11. German. doi: 10.1007/s00292-022-01175-0. Epub ahead of print.
    • Review. [Article in German]

    • Dr. Dorff on the Investigation of PARP Inhibitors in mCRPC.
    • Dorff TB.
    • OncLive. OncLive TV. 2023 Jan 10.

    • An international, multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes.
    • Cheeseman S, Levick B, Sopwith W, Fenton H, Nam EJ, Kim DK, Lim S, Martin E, FRENEL JS, Bocquet F, Kubelac P, Achimas-Cadariu P, Vlad C, Chevrier M, Rouzier R, Carton M, Savva-Bordalo J, Magalhães M, Borges M, Wolf A, Becker S, Niklas N, Guergova-Kuras M, Hall G.
    • Front Oncol. 2023 Jan 9;12:1114435. doi: 10.3389/fonc.2023.1114435.

    • Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China.
    • Wang DF, Shi XW, Zhang C, Zhang J, Liu H, Huang JM, Zhang GN, Wen QL.
    • Gynecol Oncol. 2023 Jan 4;170:25-31. doi: 10.1016/j.ygyno.2022.12.014. Epub ahead of print.

    • Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish Expanded-Access Programme.
    • Cueva JF, Palacio I, Churruca C, Herrero A, Pardo B, Constenla M, Santaballa A, Manso L, Estévez P, Maximiano C, Legerén M, Marquina G, de Juan A, Quindós M, Sánchez L, Barquin A, Fernández I, Martín C, Juárez A, Martín T, García Y, Yubero A, Gallego A, Martínez Bueno A, Guerra E, González-Martín A.
    • Eur J Cancer. 2023 Jan 1. doi: 10.1016/j.ejca.2022.12.023. Epub ahead of print.

    Related:

    •• Identifier: NCT04546373: Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 9.)

    • Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
    • Shu T, Zhou Z, Bai J, Xiao X, Gao M, Zhang N, Wang H, Xia X, Gao Y, Zheng H.
    • Gynecol Oncol. 2023 Jan;168:135-143. doi: 10.1016/j.ygyno.2022.11.013. Epub 2022 Nov 25.

    • Ferroptosis synergistically sensitizes wee1 inhibitors: a bibliometric study.
    • Xu R, Wu X, Zhao Q, Yang Q.
    • Am J Transl Res. 2022 Dec 15;14(12):8473-8488.

    • Sociodemographic, Clinical, and Variation Outcomes for Breast Cancer and Breast Cancer-Related Mutations in a Ten-Year Cohort From Neiva, Huila, Colombia.
    • Olaya J, Sanjuan J, Torres-Lopez D, Olaya L, Gutierrez-Vargas M, Olaya G, Olaya JD.
    • Cureus. 2022 Dec 6;14(12):e32257. doi: 10.7759/cureus.32257.

    • LitAlert ~~ GeneLit.com

    • Predictors of Women’s Intentions to Communicate Updated Genetic Test Results to Immediate and Extended Family Members.
    • Winskill C, Goodman MS, Daly BM, Elrick A, Mooney R, Espinel W, Kohlmann W, Kaphingst KA.
    • Public Health Genomics. 2023 Jan 14 :1-20. doi: 10.1159/000528522. Epub ahead of print.

    • Adding a genetic counseling assistant improves efficiency of hereditary cancer genetic counseling without impacting patient experience.
    • Cohen SA, Nixon DM, Lichtenberg E.
    • J Genet Couns. 2023 Jan 8. doi: 10.1002/jgc4.1671. Epub ahead of print.

    • Genetic Testing in the Latinx community: Impact of acculturation and provider relationships.
    • Ioffe YJ, Hong L, Joachim-Célestin M, Soret C, Montgomery S, Unternaehrer JJ.
    • Gynecol Oncol. 2022 Dec 26;169:125-130. doi: 10.1016/j.ygyno.2022.12.001. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Assessing Breast and Ovarian Cancer Risk Prior to Gender-Affirming Surgery.
    • Cortina CS.
    • JAMA Surg. 2023 Jan 11. doi: 10.1001/jamasurg.2022.5447. Epub ahead of print.
    • Commentary

    • Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom [Clinically relevant molecular pathological diagnostics in breast cancer].
    • Rodepeter FR, Teply-Szymanski J, Romey M, Grass A, Erber R, Lebeau A, Mack EKM, Tarawneh TS, Gremke N, Boekhoff J, Wündisch T, Wagner U, Jank P, Denkert C.
    • Pathologie (Heidelb). 2023 Jan 11. German. doi: 10.1007/s00292-022-01175-0. Epub ahead of print.
    • Review. [Article in German]

    • Adding a genetic counseling assistant improves efficiency of hereditary cancer genetic counseling without impacting patient experience.
    • Cohen SA, Nixon DM, Lichtenberg E.
    • J Genet Couns. 2023 Jan 8. doi: 10.1002/jgc4.1671. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
    • Bellier C, Gladieff L, Le Du F, Berton D, Bonnard C, Suau D, Richard AC, Brenner O, Lahouegue A, Freyer G, Floquet A, Frank S, Kfoury M.
    • Drugs Real World Outcomes. 2023 Jan 11. doi: 10.1007/s40801-022-00349-9. Epub ahead of print.

    • Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom [Clinically relevant molecular pathological diagnostics in breast cancer].
    • Rodepeter FR, Teply-Szymanski J, Romey M, Grass A, Erber R, Lebeau A, Mack EKM, Tarawneh TS, Gremke N, Boekhoff J, Wündisch T, Wagner U, Jank P, Denkert C.
    • Pathologie (Heidelb). 2023 Jan 11. German. doi: 10.1007/s00292-022-01175-0. Epub ahead of print.
    • Review. [Article in German]

    • Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study.
    • Zhang C, Zhu D, Qu Y, Shi M, Ma J, Peng Y, Zhu B, Tao H, Ma T, Hou T.
    • J Med Genet. 2023 Jan 10:jmg-2022-108816. doi: 10.1136/jmg-2022-108816. Epub ahead of print.

    • Dr. Dorff on the Investigation of PARP Inhibitors in mCRPC.
    • Dorff TB.
    • OncLive. OncLive TV. 2023 Jan 10.

    • Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China.
    • Wang DF, Shi XW, Zhang C, Zhang J, Liu H, Huang JM, Zhang GN, Wen QL.
    • Gynecol Oncol. 2023 Jan 4;170:25-31. doi: 10.1016/j.ygyno.2022.12.014. Epub ahead of print.

    • Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish Expanded-Access Programme.
    • Cueva JF, Palacio I, Churruca C, Herrero A, Pardo B, Constenla M, Santaballa A, Manso L, Estévez P, Maximiano C, Legerén M, Marquina G, de Juan A, Quindós M, Sánchez L, Barquin A, Fernández I, Martín C, Juárez A, Martín T, García Y, Yubero A, Gallego A, Martínez Bueno A, Guerra E, González-Martín A.
    • Eur J Cancer. 2023 Jan 1. doi: 10.1016/j.ejca.2022.12.023. Epub ahead of print.

    Related:

    •• Identifier: NCT04546373: Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 9.)

    • Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
    • Shu T, Zhou Z, Bai J, Xiao X, Gao M, Zhang N, Wang H, Xia X, Gao Y, Zheng H.
    • Gynecol Oncol. 2023 Jan;168:135-143. doi: 10.1016/j.ygyno.2022.11.013. Epub 2022 Nov 25.

    • Sociodemographic, Clinical, and Variation Outcomes for Breast Cancer and Breast Cancer-Related Mutations in a Ten-Year Cohort From Neiva, Huila, Colombia.
    • Olaya J, Sanjuan J, Torres-Lopez D, Olaya L, Gutierrez-Vargas M, Olaya G, Olaya JD.
    • Cureus. 2022 Dec 6;14(12):e32257. doi: 10.7759/cureus.32257.

    • LitAlert ~~ GeneLit.com

    • Predictors of Women’s Intentions to Communicate Updated Genetic Test Results to Immediate and Extended Family Members.
    • Winskill C, Goodman MS, Daly BM, Elrick A, Mooney R, Espinel W, Kohlmann W, Kaphingst KA.
    • Public Health Genomics. 2023 Jan 14 :1-20. doi: 10.1159/000528522. Epub ahead of print.

    • Assessing Breast and Ovarian Cancer Risk Prior to Gender-Affirming Surgery.
    • Cortina CS.
    • JAMA Surg. 2023 Jan 11. doi: 10.1001/jamasurg.2022.5447. Epub ahead of print.
    • Commentary

    • January 2023: Awareness of genetic testing – results and analysis from the 2020 Health Information National Trends Survey.
    • Mechanic L, Helzlsouer K.
    • Genet Med. GenePOD. 2023 Jan 9.

    Related:

    •• Original research:

    Awareness and use of genetic testing: An analysis of the Health Information National Trends Survey 2020.

    • Adding a genetic counseling assistant improves efficiency of hereditary cancer genetic counseling without impacting patient experience.
    • Cohen SA, Nixon DM, Lichtenberg E.
    • J Genet Couns. 2023 Jan 8. doi: 10.1002/jgc4.1671. Epub ahead of print.

    • Genetic Testing in the Latinx community: Impact of acculturation and provider relationships.
    • Ioffe YJ, Hong L, Joachim-Célestin M, Soret C, Montgomery S, Unternaehrer JJ.
    • Gynecol Oncol. 2022 Dec 26;169:125-130. doi: 10.1016/j.ygyno.2022.12.001. Epub ahead of print.